Esomeprazole inhibits liver inflammation and carcinogenesis by suppressing farnesoid X receptors and NF-κB signaling
Our study provides insight into the potential therapeutic effects of esomeprazole on hepatic inflammation and carcinogenesis by inhibiting LPS-induced NF-κB and FXR expression in HepG2 cells.
Authors
- Yen-Chun Peng (ORCID: https://orcid.org/0000-0002-8993-3039)
- Yi-Wen Hung (ORCID: https://orcid.org/0000-0002-6154-8315)
- Yi‐Chin Yang (ORCID: https://orcid.org/0000-0002-9651-3761)
- Chien-Chang Lu
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Chung Hsing University (TW)
- China Medical University (TW)
- Taichung Veterans General Hospital (TW)
- China Medical University Hospital (TW)
Publication Details
- Journal
- Advances in Clinical and Experimental Medicine
- Published
- 2024-12-04
- DOI
- https://doi.org/10.17219/acem/191596
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00